1. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis
- Author
-
Joseph L. Witztum, Zia Yaqoob, Santica M. Marcovina, Manjinder S. Sandhu, Asif Rasheed, Danish Saleheen, Sotirios Tsimikas, Faisal Majeed, Atif Imran, Fazal-ur-Rehman Memon, Khan Shah Zaman, Philippe M. Frossard, Anis Memon, Daniel J. Rader, Syed Zahed Rasheed, Naveeduddin Ahmed, Saba Akhtar, John Danesh, M. Ishaq, Tahir Saghir, Syed Nadeem Hasan Rizvi, Adam Taleb, Nadeem Qamar, Philip C Haycock, Wei Zhao, Nadeem Hayyat Mallick, Shahid Abbas, Khalid Mahmood, Sandhu, Manjinder [0000-0002-2725-142X], Danesh, John [0000-0003-1158-6791], and Apollo - University of Cambridge Repository
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Apolipoprotein B ,Genotype ,Endocrinology, Diabetes and Metabolism ,Myocardial Infarction ,Coronary Disease ,030204 cardiovascular system & hematology ,Apoprotein(a) ,Polymorphism, Single Nucleotide ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Polymorphism (computer science) ,Risk Factors ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Protein Isoforms ,Genetic Predisposition to Disease ,Pakistan ,Myocardial infarction ,biology ,business.industry ,Incidence ,Case-control study ,Articles ,Odds ratio ,Lipoprotein(a) ,Mendelian Randomization Analysis ,Middle Aged ,medicine.disease ,3. Good health ,030104 developmental biology ,Phenotype ,Case-Control Studies ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Female ,business ,Biomarkers ,Lipoprotein - Abstract
Background The lipoprotein(a) pathway is a causal factor in coronary heart disease. We used a genetic approach to distinguish the relevance of two distinct components of this pathway, apolipoprotein(a) isoform size and circulating lipoprotein(a) concentration, to coronary heart disease. Methods In this mendelian randomisation study, we measured lipoprotein(a) concentration and determined apolipoprotein(a) isoform size with a genetic method (kringle IV type 2 [KIV2] repeats in the LPA gene) and a serum-based electrophoretic assay in patients and controls (frequency matched for age and sex) from the Pakistan Risk of Myocardial Infarction Study (PROMIS). We calculated odds ratios (ORs) for myocardial infarction per 1-SD difference in either LPA KIV2 repeats or lipoprotein(a) concentration. In a genome-wide analysis of up to 17 503 participants in PROMIS, we identified genetic variants associated with either apolipoprotein(a) isoform size or lipoprotein(a) concentration. Using a mendelian randomisation study design and genetic data on 60 801 patients with coronary heart disease and 123 504 controls from the CARDIoGRAMplusC4D consortium, we calculated ORs for myocardial infarction with variants that produced similar differences in either apolipoprotein(a) isoform size in serum or lipoprotein(a) concentration. Finally, we compared phenotypic versus genotypic ORs to estimate whether apolipoprotein(a) isoform size, lipoprotein(a) concentration, or both were causally associated with coronary heart disease. Findings The PROMIS cohort included 9015 patients with acute myocardial infarction and 8629 matched controls. In participants for whom KIV2 repeat and lipoprotein(a) data were available, the OR for myocardial infarction was 0·93 (95% CI 0·90–0·97; p
- Published
- 2017
- Full Text
- View/download PDF